Is the Eclipx Group share price in the buy zone yet?

The Eclipx Group Ltd (ASX: ECX) share price fell 56% after a negative ASX update before rebounding to $1.24 per share at market close – is it in the buy zone?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Eclipx Group Ltd (ASX: ECX) share price fell 56% in one day to $0.57 per share after a negative ASX update before rebounding to $1.24 per share at market close – but is it in the buy zone?

What happened to Eclipx to start the year?

In mid-March this year, Eclipx emerged from its trading halt with an update announcing a 42.4% decrease in net profit after tax and adjustments (NPATA), compared to the first five months of FY18.

The company also announced that its financial performance had "softened" since its 29 January 2019 update as its Grays Industrial and Insolvency segments continued to underperform, and that it was looking at divesting non-core assets.

Both Eclipx management and McMillan Shakespeare Limited (ASX: MMS) announced that a planned merger was "unlikely" as McMillan pointed to several key issues in Eclipx's trading update, including the NPATA decline and ongoing underperformance.

Could the Eclipx share price be in the buy zone?

I'm not personally in the game of distressed investing, but so far Eclipx looks like it might be back in the buy zone.

If you had managed to buy in the dip immediately following the crash, you would have netted yourself a tidy 117% profit in just a few months, which is greater than the share price performance of Afterpay Touch Group Ltd (ASX: APT) or Appen Ltd (ASX: APX) over the last 6 months.

Eclipx management has made a few structural changes and look to be plotting a path back to profitability, after non-cash impairment of assets and a change of senior leadership (including the CFO) in the subsequent months.

Eclipx's first-half earnings (released at the end of May) were indicative of the difficult 6 months the company has endured, but if market conditions hold and the company can stick to its strategy, I think the full-year accounts could show improved performance and a share price rebound for brave investors.

Motley Fool contributor Lachlan Hall has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

three men stand on a winner's podium with medals around their necks with their hands raised in triumph.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy end to the trading week this Friday.

Read more »

A business person directs a pointed finger upwards on a rising arrow on a bar graph.
Share Gainers

3 ASX 200 stocks storming higher in this week's sinking market

Investors have sent these three ASX 200 stocks soaring this week. But why?

Read more »

Two smiling work colleagues discuss an investment at their office.
Share Gainers

Why 4DMedical, Develop Global, EOS, and Maas shares are racing higher today

These shares are ending the week on a high. But why?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Up 657% in a year, 4DMedcial shares rocketing another 20% today on big US news

ASX investors can’t get enough of 4DMedical shares today. Let’s see why.

Read more »

A neon sign says 'Top Ten'.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX 200 broke its losing streak to inch higher today.

Read more »

Wife and husband with a laptop on a sofa over the moon at good news.
Consumer Staples & Discretionary Shares

Bapcor shares soar 12% on the appointment of a new CEO

The market’s strong reaction reflects a clear message: investors are ready for a reset.

Read more »

A young woman drinking coffee in a cafe smiles as she checks her phone.
Share Gainers

Why Bapcor, IDP Education, Netwealth, and Ora Banda shares are pushing higher today

These shares are catching the eye with solid gains on Thursday. But why are they rising?

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This ASX stock is going parabolic, and I think it's still a buy

4DMedical shares are up nearly 500% in 2025, but improving revenue visibility suggests the growth story may not be over.

Read more »